Biomarkers of Renal Cancer

Summary

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Eligibility

Inclusion Criteria for renal-mass patients:

* Men and women over 18 years of age
* Diagnosis of first episode of renal mass
* Caucasian race
* Signed, informed consent

Exclusion Criteria renal-mass patients:

* Any other concomitant cancer or history of active cancer in the last 5 years
* Oncological genetic syndrome
* Previous history of renal tumour
* Urothelial cancer
* End-stage renal disease on hemodialysis
* Bilateral renal cell carcinoma

Inclusion Criteria for control subjects:

* Men and women over 18 years of age
* Caucasian race
* Living kidney donor or patient with urological functional diseases (e.g. kidney stones, benign prostate hypertrophy, etc..)
* Signed, informed consent

Exclusion criteria for control subjects:

* History of active cancer in the last 5 years
* Oncological genetic syndrome
* End-stage renal disease on hemodialysis or peritoneal dialysis

Conditions5

Browse More Trials